Key Documents

View All Documentation

Y0001006

Dydrogesterone impurity B

Name: Dydrogesterone impurity B
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Pregna-4,6-diene-3,20-dione

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₁H₂₈O₂

CAS Number:

1162-56-7

Molecular Weight:

312.45

UNSPSC Code:

41116107

NACRES:

NA.24

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

dydrogesterone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1CC[C@@]2([C@@H]3[C@H]([C@H]4[C@@]([C@H](CC4)C(=O)C)(CC3)C)C=CC2=C1)C

InChI

1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1

InChI key

JGMOKGBVKVMRFX-LEKSSAKUSA-N

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dydrogesterone impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

GHS08

signalword

Danger

hcodes

H351,H360FD,H362

pcodes

P202 - P260 - P263 - P264 - P280 - P308 + P313

Hazard Classifications

Carc. 2 - Lact. - Repr. 1A

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

[Medication of the month. Femoston Low (0.5 mg estradiol plus 2.5 mg dydrogesterone) for menopausal hormonal replacement therapy].

A J Scheen et al.

Revue medicale de Liege, 66(4), 209-214 (2011-06-07)

Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston Low is

Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality.

A R Genazzani et al.

Climacteric : the journal of the International Menopause Society, 14(6), 661-668 (2011-09-29)

Sexual desire is affected by endocrine and psychosocial factors. Menopausal hormonal changes are relevant to the causes of sexual dysfunction during reproductive aging. To evaluate the effects of different types of hormonal replacement therapy (HRT) on sexual function, frequency of

Dydrogesterone exerts endothelial anti-inflammatory actions decreasing expression of leukocyte adhesion molecules.

Xiao-Dong Fu et al.

Molecular human reproduction, 18(1), 44-51 (2011-10-06)

Clinical observations and basic studies show that progesterone and progestins have a variable influence on endothelial function. Dydrogesterone (DG) is a widely used progestin, but its endothelial actions have not been thoroughly assessed. In this study, we investigated the effects

View All Related Papers

Global Trade Item Number

SKU	GTIN
Y0001006	04061833817742